Literature DB >> 34587750

Epigenetic Age and the Risk of Incident Atrial Fibrillation.

Jason D Roberts1,2, Eric Vittinghoff3, Ake T Lu4, Alvaro Alonso5, Biqi Wang6,7, Colleen M Sitlani8,9, Pedrum Mohammadi-Shemirani1,10,11, Myriam Fornage12, Jelena Kornej6,13, Jennifer A Brody8,9, Dan E Arking14, Honghuang Lin6,15, Susan R Heckbert8,16, Ivana Prokic17, Mohsen Ghanbari17, Allan C Skanes2, Traci M Bartz8,18,9, Marco V Perez19, Kent D Taylor20, Steven A Lubitz21,22,23, Patrick T Ellinor21,22,23, Kathryn L Lunetta7, James S Pankow24, Guillaume Paré1,25,11, Nona Sotoodehnia8,26,16,9, Emelia J Benjamin6,27,13, Steve Horvath28, Gregory M Marcus29.   

Abstract

BACKGROUND: The most prominent risk factor for atrial fibrillation (AF) is chronological age; however, underlying mechanisms are unexplained. Algorithms using epigenetic modifications to the human genome effectively predict chronological age. Chronological and epigenetic predicted ages may diverge in a phenomenon referred to as epigenetic age acceleration (EAA), which may reflect accelerated biological aging. We sought to evaluate for associations between epigenetic age measures and incident AF.
METHODS: Measures for 4 epigenetic clocks (Horvath, Hannum, DNA methylation [DNAm] PhenoAge, and DNAm GrimAge) and an epigenetic predictor of PAI-1 (plasminogen activator inhibitor-1) levels (ie, DNAm PAI-1) were determined for study participants from 3 population-based cohort studies. Cox models evaluated for associations with incident AF and results were combined via random-effects meta-analyses. Two-sample summary-level Mendelian randomization analyses evaluated for associations between genetic instruments of the EAA measures and AF.
RESULTS: Among 5600 participants (mean age, 65.5 years; female, 60.1%; Black, 50.7%), there were 905 incident AF cases during a mean follow-up of 12.9 years. Unadjusted analyses revealed all 4 epigenetic clocks and the DNAm PAI-1 predictor were associated with statistically significant higher hazards of incident AF, though the magnitudes of their point estimates were smaller relative to the associations observed for chronological age. The pooled EAA estimates for each epigenetic measure, with the exception of Horvath EAA, were associated with incident AF in models adjusted for chronological age, race, sex, and smoking variables. After multivariable adjustment for additional known AF risk factors that could also potentially function as mediators, pooled EAA measures for 2 clocks remained statistically significant. Five-year increases in EAA measures for DNAm GrimAge and DNAm PhenoAge were associated with 19% (adjusted hazard ratio [HR], 1.19 [95% CI, 1.09-1.31]; P<0.01) and 15% (adjusted HR, 1.15 [95% CI, 1.05-1.25]; P<0.01) higher hazards of incident AF, respectively. Mendelian randomization analyses for the 5 EAA measures did not reveal statistically significant associations with AF.
CONCLUSIONS: Our study identified adjusted associations between EAA measures and incident AF, suggesting that biological aging plays an important role independent of chronological age, though a potential underlying causal relationship remains unclear. These aging processes may be modifiable and not constrained by the immutable factor of time.

Entities:  

Keywords:  aging; atrial fibrillation; epigenomics; genetics

Mesh:

Year:  2021        PMID: 34587750      PMCID: PMC8671333          DOI: 10.1161/CIRCULATIONAHA.121.056456

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   39.918


  41 in total

1.  Estimating the proportion of treatment effect explained by a surrogate marker.

Authors:  D Y Lin; T R Fleming; V De Gruttola
Journal:  Stat Med       Date:  1997-07-15       Impact factor: 2.373

Review 2.  Translational Challenges in Atrial Fibrillation.

Authors:  Jordi Heijman; Jean-Baptiste Guichard; Dobromir Dobrev; Stanley Nattel
Journal:  Circ Res       Date:  2018-03-02       Impact factor: 17.367

3.  Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993-2007.

Authors:  Jonathan P Piccini; Bradley G Hammill; Moritz F Sinner; Paul N Jensen; Adrian F Hernandez; Susan R Heckbert; Emelia J Benjamin; Lesley H Curtis
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2012-01-10

4.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.

Authors:  P A Wolf; R D Abbott; W B Kannel
Journal:  Stroke       Date:  1991-08       Impact factor: 7.914

5.  The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

Authors: 
Journal:  Am J Epidemiol       Date:  1989-04       Impact factor: 4.897

Review 6.  Dynamic DNA methylation: In the right place at the right time.

Authors:  Chongyuan Luo; Petra Hajkova; Joseph R Ecker
Journal:  Science       Date:  2018-09-28       Impact factor: 47.728

7.  Epigenome-wide scans identify differentially methylated regions for age and age-related phenotypes in a healthy ageing population.

Authors:  Jordana T Bell; Pei-Chien Tsai; Tsun-Po Yang; Ruth Pidsley; James Nisbet; Daniel Glass; Massimo Mangino; Guangju Zhai; Feng Zhang; Ana Valdes; So-Youn Shin; Emma L Dempster; Robin M Murray; Elin Grundberg; Asa K Hedman; Alexandra Nica; Kerrin S Small; Emmanouil T Dermitzakis; Mark I McCarthy; Jonathan Mill; Tim D Spector; Panos Deloukas
Journal:  PLoS Genet       Date:  2012-04-19       Impact factor: 5.917

8.  Introduction to the Analysis of Survival Data in the Presence of Competing Risks.

Authors:  Peter C Austin; Douglas S Lee; Jason P Fine
Journal:  Circulation       Date:  2016-02-09       Impact factor: 29.690

9.  Multi-ethnic genome-wide association study for atrial fibrillation.

Authors:  Carolina Roselli; Mark D Chaffin; Lu-Chen Weng; Stefanie Aeschbacher; Gustav Ahlberg; Christine M Albert; Peter Almgren; Alvaro Alonso; Christopher D Anderson; Krishna G Aragam; Dan E Arking; John Barnard; Traci M Bartz; Emelia J Benjamin; Nathan A Bihlmeyer; Joshua C Bis; Heather L Bloom; Eric Boerwinkle; Erwin B Bottinger; Jennifer A Brody; Hugh Calkins; Archie Campbell; Thomas P Cappola; John Carlquist; Daniel I Chasman; Lin Y Chen; Yii-Der Ida Chen; Eue-Keun Choi; Seung Hoan Choi; Ingrid E Christophersen; Mina K Chung; John W Cole; David Conen; James Cook; Harry J Crijns; Michael J Cutler; Scott M Damrauer; Brian R Daniels; Dawood Darbar; Graciela Delgado; Joshua C Denny; Martin Dichgans; Marcus Dörr; Elton A Dudink; Samuel C Dudley; Nada Esa; Tonu Esko; Markku Eskola; Diane Fatkin; Stephan B Felix; Ian Ford; Oscar H Franco; Bastiaan Geelhoed; Raji P Grewal; Vilmundur Gudnason; Xiuqing Guo; Namrata Gupta; Stefan Gustafsson; Rebecca Gutmann; Anders Hamsten; Tamara B Harris; Caroline Hayward; Susan R Heckbert; Jussi Hernesniemi; Lynne J Hocking; Albert Hofman; Andrea R V R Horimoto; Jie Huang; Paul L Huang; Jennifer Huffman; Erik Ingelsson; Esra Gucuk Ipek; Kaoru Ito; Jordi Jimenez-Conde; Renee Johnson; J Wouter Jukema; Stefan Kääb; Mika Kähönen; Yoichiro Kamatani; John P Kane; Adnan Kastrati; Sekar Kathiresan; Petra Katschnig-Winter; Maryam Kavousi; Thorsten Kessler; Bas L Kietselaer; Paulus Kirchhof; Marcus E Kleber; Stacey Knight; Jose E Krieger; Michiaki Kubo; Lenore J Launer; Jari Laurikka; Terho Lehtimäki; Kirsten Leineweber; Rozenn N Lemaitre; Man Li; Hong Euy Lim; Henry J Lin; Honghuang Lin; Lars Lind; Cecilia M Lindgren; Marja-Liisa Lokki; Barry London; Ruth J F Loos; Siew-Kee Low; Yingchang Lu; Leo-Pekka Lyytikäinen; Peter W Macfarlane; Patrik K Magnusson; Anubha Mahajan; Rainer Malik; Alfredo J Mansur; Gregory M Marcus; Lauren Margolin; Kenneth B Margulies; Winfried März; David D McManus; Olle Melander; Sanghamitra Mohanty; Jay A Montgomery; Michael P Morley; Andrew P Morris; Martina Müller-Nurasyid; Andrea Natale; Saman Nazarian; Benjamin Neumann; Christopher Newton-Cheh; Maartje N Niemeijer; Kjell Nikus; Peter Nilsson; Raymond Noordam; Heidi Oellers; Morten S Olesen; Marju Orho-Melander; Sandosh Padmanabhan; Hui-Nam Pak; Guillaume Paré; Nancy L Pedersen; Joanna Pera; Alexandre Pereira; David Porteous; Bruce M Psaty; Sara L Pulit; Clive R Pullinger; Daniel J Rader; Lena Refsgaard; Marta Ribasés; Paul M Ridker; Michiel Rienstra; Lorenz Risch; Dan M Roden; Jonathan Rosand; Michael A Rosenberg; Natalia Rost; Jerome I Rotter; Samir Saba; Roopinder K Sandhu; Renate B Schnabel; Katharina Schramm; Heribert Schunkert; Claudia Schurman; Stuart A Scott; Ilkka Seppälä; Christian Shaffer; Svati Shah; Alaa A Shalaby; Jaemin Shim; M Benjamin Shoemaker; Joylene E Siland; Juha Sinisalo; Moritz F Sinner; Agnieszka Slowik; Albert V Smith; Blair H Smith; J Gustav Smith; Jonathan D Smith; Nicholas L Smith; Elsayed Z Soliman; Nona Sotoodehnia; Bruno H Stricker; Albert Sun; Han Sun; Jesper H Svendsen; Toshihiro Tanaka; Kahraman Tanriverdi; Kent D Taylor; Maris Teder-Laving; Alexander Teumer; Sébastien Thériault; Stella Trompet; Nathan R Tucker; Arnljot Tveit; Andre G Uitterlinden; Pim Van Der Harst; Isabelle C Van Gelder; David R Van Wagoner; Niek Verweij; Efthymia Vlachopoulou; Uwe Völker; Biqi Wang; Peter E Weeke; Bob Weijs; Raul Weiss; Stefan Weiss; Quinn S Wells; Kerri L Wiggins; Jorge A Wong; Daniel Woo; Bradford B Worrall; Pil-Sung Yang; Jie Yao; Zachary T Yoneda; Tanja Zeller; Lingyao Zeng; Steven A Lubitz; Kathryn L Lunetta; Patrick T Ellinor
Journal:  Nat Genet       Date:  2018-06-11       Impact factor: 38.330

10.  DNA methylation GrimAge strongly predicts lifespan and healthspan.

Authors:  Ake T Lu; Austin Quach; James G Wilson; Alex P Reiner; Abraham Aviv; Kenneth Raj; Lifang Hou; Andrea A Baccarelli; Yun Li; James D Stewart; Eric A Whitsel; Themistocles L Assimes; Luigi Ferrucci; Steve Horvath
Journal:  Aging (Albany NY)       Date:  2019-01-21       Impact factor: 5.682

View more
  2 in total

1.  Accelerated Epigenetic Aging and Incident Atrial Fibrillation: New Outlook on an Immutable Risk Factor?

Authors:  Cavin K Ward-Caviness
Journal:  Circulation       Date:  2021-12-13       Impact factor: 39.918

Review 2.  Epigenetics in Alzheimer's Disease.

Authors:  Xiaodie Gao; Qiang Chen; Hua Yao; Jie Tan; Zheng Liu; Yan Zhou; Zhenyou Zou
Journal:  Front Aging Neurosci       Date:  2022-06-23       Impact factor: 5.702

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.